Last month, Bayer received regulatory approval for haemophilia A treatment, Jivi, in the US and Japan.
Haemophilia A is a genetic disorder caused by a missing or defective clotting protein, factor VIII.
Jivi is classified as a recombinant factor VIII (rFVIII) product and joins Bayer’s two rFVIII treatments already on the market – Kogenate and Kovaltry. Bayer manufactures all three treatments at the Californian facility.
Earlier this week, Bayer announced its regulatory success in the haemophilia field had prompted an internal restructure, which will see headcount in Berkely reduced by 227.
“Our transition into commercial production with three products has resulted in the need for organisational changes to enable these efficiencies,” a spokesperson told us in an emailed statement.
“The decision will not impact product availability as we remain committed to providing a portfolio of treatment options to serve the individual needs of the haemophilia community,” the spokesperson added.
In other restructuring news, earlier this year Bayer announced plans to transfer technology from a facility in Ansung, South Korea, to Berlin, and divested its prescription dermatology unit to Danish firm, LEO Pharma.